5 Best ETF Charts Of Q4 Earnings

The Q4 earnings season has reached its tail end with 97.1% of the S&P 500 index market capitalization that has reported so far up 14% on 8.5% revenue growth, with 77.2% beating EPS estimates and 76% coming ahead of top-line expectations. Earnings and revenue growth rates are much higher for the same group of companies than in the past few quarters. Additionally, earnings and revenue surprises are also tracking above historical levels.

Investors should note that the gap between adjusted operating earnings and GAAP earnings is the widest in recent years due to huge one-time charges related to the new tax law.

Given this, several equity ETFs have impressed with their performances and generated handsome returns over the trailing one month even after being hit by the market rout triggered by inflation fears and higher-than-expected rates hike. While there are winners in many corners of the space, below are five ETFs that buoyed up on robust earnings results.

In addition, we have given a chart for their one-month performance and compared them with the broad market fund (SPY – Free Report) and the broad sector.

First Trust Nasdaq Semiconductor ETF (FTXL – Free Report)

This fund offers exposure to the most-liquid U.S. semiconductor securities based on volatility, value and growth. Total earnings for the broad technology sector are up 23.4% on 10.8% higher revenues with a blended beat of 86.4%. Most of the growth comes from semiconductor companies, expected to post 68.8% earnings growth in Q4, representing an incredible surge from 33.8% earnings growth in the year-ago quarter. Given this, FTXL has gained 15.5% in the past month and boasts a Zacks ETF Rank #1 (Strong Buy).

Loncar Cancer Immunotherapy ETF (CNCR – Free Report)

This product provides exposure to a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. The wave of mergers and acquisition talks as well as solid earnings from companies like Nektar Therapeutics (NKTR – Free Report) , Jounce Therapeutics (JNCE – Free Report) , Macrogenics (MGNX – Free Report) and Gilead Sciences (GLD – Free Report) provided a boost to the fund’s portfolio. As a result, CNCR was up 13.3% over the past month and carries a Zacks ETF Rank #2 (Buy) with a High risk outlook.